Puma's early Nerlynx launch raises doubts of a takeover

06:27 EDT 1 Aug 2017 | BioPharmaDive

The company's decision to commercialize its breast cancer drug dampens the prospect of a near-term acquisition, according to a recent analyst report. 

Original Article: Puma's early Nerlynx launch raises doubts of a takeover


More From BioPortfolio on "Puma's early Nerlynx launch raises doubts of a takeover"

Quick Search

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...